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Synthesis and evaluation of bis(imino)anthracene
derivatives as G-quadruplex ligands†
Tomris Coban, Cameron Robertson, Sianne Schwikkard,
Richard Singer and Adam LeGresley *
The synthesis of a small number of bis(imino)anthracene derivatives is reported. They were evaluated via
NMR for binding efficacy to the G-quadruplex-forming oligonucleotide sequence (TTGGGTT) and show
activity against the HeLa cancer cell line. These novel ligands are compared to previously synthesised
G-quadruplex ligands that target telomeres and oncogenes.
Introduction
G-quadruplexes (G4) became biologically relevant in the 1980s
mostly based on the seminal work undertaken by Dr.
Elizabeth Blackburn which showed telomeric DNA forms non-
Watson–Crick guanine–guanine base-paired intramolecular
DNA structures.1 This discovery led to increased research
interest and initiated interest in the field of G-quadruplex
research.2 G-Quadruplex DNA structures heralded a new
approach in anticancer drug design and development through
the targeting of secondary DNA structures.3 It has been
demonstrated that G-quadruplexes are present in genes that
have been shown to be overexpressed in several different
cancers, the stabilisation of which can effectively act as a
switch for these genes.4–8 The first telomere interacting
molecular structure was found to be
2,6-diamidoanthraquinone derivatives synthesised by Sun
et al.9 These observations have led to an exponential growth
in the development of synthetic small molecules for
G-quadruplex binding and represent a rational approach to
lead molecule design. Despite a large and diverse libraries of
potential lead compounds having been reported, the search
for G-tetrad selective compounds that can indirectly inhibit
telomerase extension of DNA in cancer cells continues.
The principle motifs of a selective G-quadruplex ligand
have been reported by a number of research groups.10–14
These include the requirement for planar aromatic systems
and distal ionisable amine groups to interact with the
phosphate backbone of the quadruplex DNA. Our intention
was to couple a range of ionisable amine groups a–h to
anthracene-9,10-dicarbaldehdye 1 and probe their selectivity
for quadruplex over duplex DNA and to test them for
cytotoxicity in HeLa cells (Fig. 1).
The reversible nature of the imine reaction facilitates the
future establishment of a dynamic combinatorial library for
this class of ligand, which may enable the in situ
amplification of a specific (bis)imino compound from our
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Fig. 1 Simplified scheme for imine coupling to acrylate as done for
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anthracene derivative depending on the thermodynamics
associated with exposure to quadruplex over duplex DNA.
However, in this manuscript we report the formation and
testing of a small static combinatorial library based on 1.
Results
Reaction of a series of amines to 1 was achieved using
literature methods.15 The amines were selected owing to their
potential for selectivity for the G-quadruplex e.g. Tryptamine
is a known monoamino alkaloid which was selected based
upon its amino group position in the ring system (see ESI†
S1 and S2).
From Table 1, we show 3 compounds 2f, 2g and 2h were
not successfully synthesised due to solubility issues.
Before biochemical and in vitro analysis, the imines were
tested for aqueous stability in Dulbecco's modified Eagle's
medium (DMEM). Using an internal standard (TSP), after
qNMR analysis at time point 0 and 24 h later no breakdown
was observed with no significant concentration changes
detected in triplicate experiments.16
Compounds 2a–2e were evaluated for G-quadruplex
interaction using NMR titration studies with d(TTGGGTT)4
with intercalation comparisons made against doxorubicin
and nemorubicin (see ESI† S1). Previous literature with
d(TTGGGTT)4 has demonstrated that G-quadruplex ligands
intercalate specifically at the point between G5–T6.17 Large
broadening of G5 imino proton peaks, accompanied with an
up-field shift, shows this. We also see the peaks for T6
(methyl, aromatic and ribose) shifting to a lower field in
accord with the up-field shift of the G5 peaks. This change is
explained by the formation of a complex between the ligand
and the tetrad formed at G5, which pushes the T6 unit away
from the guanine π-system. This intercalation framework
agreed with ESI/MS carried out which illustrated a 1 : 1
complex.17 We see in Fig. 2, much like previous work, that
line broadening and up-field shift occurs at peaks
representative of proton G6NH (10.79 ppm) significantly,
alongside the significant peak broadening and down field
shifting of T6H6/8 and T6CH3 peaks with the addition of
proposed ligands.18
These significant changes demonstrate distinctly different
bound and unbound forms through large broadening effects
at a ratio of 0.5 : 1. There is also subtle line broadening and
up-field shifting of G4NH (11.48 ppm) and G5NH (11.15
ppm) for each ligand that shows chemical exchange between
two similar environments of bound and unbound ligand.
Maximum line broadening occurs at a ratio of 1 : 1 drug to
G-quadruplex and chemical shift difference changing up to
1 : 1 with the bound and unbound peaks being present. This
matches the effect seen by nemorubicin intercalation with
d(TTGGGTT)4 in previous literature suggesting a 1 : 1
stoichiometry. This investigation showed that the five imine
coupled ligands showed G-quadruplex intercalation with 1 : 1
stoichiometry matching that of the current cancer drugs
doxorubicin and nemorubicin (Table 2).
Compounds 2a–2e were subsequently tested against a
HeLa cancer cell line (HeLa, American Type Culture
Collection (ATCC) (ATCC® CCL-2™)) and they were all
prepared in 100, 30, 10 and 1 μM concentrations so that IC50
values could be calculated to establish whether drugs were
cytotoxic to HeLa cells (see ESI† S1).
Discussion
The ligands have different functional groups present in their
side chains; 1,3-benzodioxole, propylmorpholine,
2,5-dimetylthiazole, 3-methyl indole and piperidine
respectively, which we suspected stabilise the hydrogen bond
between the tertiary amine and oxygens of phosphate.
However, all these groups have been shown in previous
studies to demonstrate DNA and G-quadruplex intercalation
alongside anti-cancer activity. This suggests that each of
these groups may have more of an effect on IC50, than solely
the effects on hydrogen bond stabilisation.
Table 1 Comparison of yields, experiment times and structures of
specific imine coupled amine groups to anthracene core
Compound Yield (%) Time (h)
2a 78 24 h
2b 60 24 h
2c 80 12 h
2d 65 24 h
2e 75 24 h
2f — 48 h
2g — 48 h
2h — 48 h
Fig. 2 1D 1HNMR spectra, referenced to TSP, showing titration of drug compounds and d(TTAGGGT)4. A slow exchange interaction, is illustrated
with black arrows and fast exchanging interactions by blue arrows preliminary experiments were done to screen for activity and synthesised
compounds that showed activity were run in triplicate to get an average, SD and SEM values, from these results, it was shown that all 5 ligands
showed cancer activity with IC50 values ranging from (∼18–31 μM) as illustrated in Fig. 3.
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We see that the two groups can be grouped by their
absence of oxygen or sulphur, piperidine and 3-methyl indole
show quite divergent differences in ppm between bound and
unbound forms of the G4 model. These two compounds also
have 2 of the higher IC50 values of the 5 intercalating
compounds, 24 μM (2d) and 30.5 μM (2c).
Previous studies have demonstrated non-selective binding
to DNA and G4 structures where the mode of binding to
DNA, like our results, showed a 1 : 1 stoichiometry, with
Gibbs free energy calculations showing a spontaneous
intercalation which suggests a stabilising, energetically
favourable reaction.19 It was also shown that using piperidine
as a N-propylamino attached to carbazoles gave the highest
stabilizing ligands in a study.20 Interestingly, however they
did identify that there was an inverse correlation between
G-tetrad stabilization and G4 DNA selectivity.21 This is very
interesting for our results, as it could begin to explain why
we see that the relationship between the change in ppm does
not correlate completely with IC50 values, even showing an
inverse relationship to what was expected from nemorubicin
Fig. 3 Cell culture, presto blue assay results for 2a, 2b, 2c, 2d, 2e. The data shown is after 24 hour incubation of drug treated HeLa cells. Top
chart illustrates mean and SEM of HeLa cell viability at concentrations 100 to 1 μM with positive control (doxorubicin (N2)). In the top charts,
values are normalized to negative control (DMSO) at a value of 1 (cell viability). The bottom charts then show the normalized absorbance
percentage to the negative control (percentage cell viability) of log inhibitor concentration (multiplied by 10 to account for 1 μM concentration)
IC50 values and R squared values are included in the chart. Error bars indicates standard error of mean from n = 3 experiments.
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results.17 It could show that G4 ligands intercalate and
stabilise very effectively but IC50 will be increased as G4
ligand is less selective for G4 structures. This could explain
why we see piperidine having similar chemical difference
effects and stabilization effects to other compounds but has
a higher IC50. 3-Methyl indole is less investigated for this
purpose because of its role primarily as an odourant. There
are however genetic studies that show protective mechanisms
against damage by 3-methyl indole derivatives that can
induce apoptosis at low concentrations. This was shown in a
study by Nichols WK they looked at 3-methyl indole mediated
cytotoxicity in human epithelial lung cells, with CYP2F1 over
expressed.22 This is relevant to this study as it shows that
3-methyl indole has a structure activity relationship which
relates to cytotoxicity of genetically impaired cells, which
could possibly explain anti-cancer activity.22 The anti-cancer
activity of indoles has also been shown with indole groups in
isoxazolo[5′,4′:5,6]pyrido[2,3-b]indoles, which showed
significant anticancer activity comparable to standard drugs
however the mechanism of action and structure activity
relationship is yet to be investigated.23
The three groups that contained oxygen, sulphur and
nitrogen, and nitrogen and oxygen, 1,3-benzodioxole,
2,5-dimethylthiazole and N-propylmorpholine respectively,
showed a close linear correlation between their ability to
stabilise G4 structure and IC50. They also, as a group had the
best IC50 values with 1,3-benzodioxole and 2,5-dimethyl
thiazole as the best candidates for further testing. Further
synthesis and reinforcement of DNA binding potential of
1,3-benzodioxole has been illustrated by a study which
showed DNA binding was moderate to mild and suggested
that cytotoxic effects were through a different mode of action,
which supports the selectivity argument for
1,3-benzodioxole.24 They demonstrated through molecular
docking that a benzodioxole derivative had potent telomerase
inhibition alongside potent anticancer activity in human
gastric and human melanoma cell lines.25 This shows that
this group may add additional benefit through telomerase
inhibition in a different method of action to the one
investigated here with G4 stabilisation. The
2,5-dimethylthiazole has been studied extensively in the form
of the fluorescent marker thiazole orange for its intercalation
potential. It was shown in early research that thiazole orange
binds both as a monomer and dimer to DNA. Monomers of
thiazole orange stack between DNA bases. It is also shown as
the main way of binding with duplex DNA. Interestingly they
also reported binding to poly(dG) which showed binding as a
monomer and dimer as well. This supports our results
showing intercalation and stabilisation of G4 as seen in our
results.26 Selective stabilization of G4 structures by thiazole
has further been supported more recently with studies that
showed 1 : 1 stoichiometry between dye and G-tetrads in
quadruplex DNA. It also illustrated that there was a tight
complex formed between the two. Interestingly they showed
that in the presence of K+ ions, this binding seemed to
disappear.27 To attempt to rationalise the chemical shift
difference and IC50 values observed, computational
modelling of the 5 ligands with parallel (PDB entry139d) and
antiparallel (PDB entry 6IMS) quadruplex structures was
undertaken using Autodock Vina both in conjunction with












2a 0.09 0.17 −0.04 −0.08 −0.2
2b 0.093 0.22 −0.066 −0.135 −0.34
2e 0.146 0.19 −0.056 −0.11 −0.24
2c 0.157 0.126 −0.06 −0.115 −0.25
2d 0.094 0.16 −0.03 −0.07 −0.13
Table 3 Comparison of IC50 values and G quadruplex chemical shift differences for compounds 2a–2e alongside Autodock Vina blind docking scores
(kCal mol−1) using Chimera and CB-Dock for parallel and antiparallel quadruplex models. Shown in order of decreasing IC50
Compound
Parallel docking score Antiparallel docking score
Chimera CB-Dock Chimera CB-Dock Δδ (ppm) IC50 (μM)
2c −6.8 −7.2 −7.3 −7.8 0.25 30.6
2b −6.4 −6.3 −6.2 −6.5 0.34 24.4
2d −6.6 −6.9 −6.4 −6.6 0.13 23.84
2e −6.7 −6.8 −6.4 −7.0 0.24 20.5
2a −8.1 −8.1 −7.7 −7.8 0.2 18
Doxorubicin17 0.31 0.374
Nemorubicin17 0.31 0.08
RHPS4 (ref. 32) — 0.2
BRACO19 (ref. 33) — 5.25
Quarfloxin34 — 4.44
BMH-21 (ref. 34) — 0.46
CX-5461 (ref. 34) — 6.89
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UCSF Chimera 1.15v and CB-Dock – these values are show in
Table 3.28–30 The docking box was chosen within Chimera to
encompass the entire quadruplex model, thus allowing Vina
to search the whole of the target space. The docking box was
larger than the upper size recommended for use with
Autodock Vina. Therefore blind docking was also carried out
using the CB-Dock web server, which uses cavity detection
based on analysis of the solvent accessible surface to identify
potential docking sites in the target, followed by the use
Autodock Vina to generate and score the ligand poses at the
detected dicking sites. Because the same scoring function is
used by both methods the docking scores are directly
comparable. The results are very close to those from
Autodock Vina and Chimera which forgoes the cavity
detection step. Details of the parameters and programs used
can be found in ESI† S1. Energy minima scores were
obtained and are shown against IC50 and Δδ values shown in
Table 3. Interestingly, ligand 2a gave the best apparent fit to
both quadruplex structures as indicated in Fig. 4. It should
be noted that there is a correlation between IC50 and all of
the docking data, with the exception of 2c, which appears to
be an outlier. There appears to be preferential binding to the
end of the quadruplex as opposed to intercalation. There is
further evidence of groove binding.
Compound 2b, which has a propylmorpholine group has
been implemented in the design of compounds for telomeric
and oncogenic G-quadruplex affinity with varying degrees of
success. It was shown through molecular docking analysis
that compounds made with propylmorpholine interact with
the groove and or loop of the G-quadruplex, which supports
our stacking hypothesis through interaction with these
external components. This study also showed inhibition in
the growth of A549 cancer cell lines with low cytotoxicity to
normal cells. This study concluded that addition of
propylmorpholine to naphthalimide supports tumor cell
cytotoxicity selectivity.21,31
Looking at Table 3, we see the IC50's of doxorubicin and
nemorubicin are much lower than the IC50 values of our
synthesised compounds, however we do see that their Δδ is
comparable to our two lowest IC50 compounds. This suggests
a similar interaction mechanism where a 1 : 1 stoichiometry,
with planar stacking on the G6 tetrad.17 This however does
show that G-quadruplex binding may start through this
stacking and be an initiating step for cytotoxicity, but we see
from these results that side chains give comparable chemical
shift differences and intercalation stoichiometry but produce
very different IC50 values. This however could be explained by
selectivity measures. Comparisons of other G-quadruplex
ligands and their IC50 values to synthesised ligands shows
promise for these compounds as scaffolds for drug discovery
as we see the synthesised compounds IC50 values are within
the same order as previously synthesised G-quadruplex
ligands.
Conclusions
The promotion of quadruplex DNA formation as observed in
solution by NMR, and initial biological testing, suggests the
class of G-quadruplex ligand based on imine coupled ligands
possess an anticancer activity. Whilst, compared to other
synthesised G-quadruplex ligands, we see a poorer IC50 value
for these preliminary imine coupled anthracene derivatives,
the propensity for intercalation to G-quadruplex and simple
synthesis allows for extensive expansion of imine coupled
anthracene derivatives as scaffolds for further modification
and drug discovery. Whilst this communication expands
incrementally on the planar anthracene arrays, already
evaluated for G-quadruplex stabilisation, there is a
requirement for further investigation to identify the specific
G-quadruplexes targeted. E.g. telomere or oncogene promoter
regions. However, as discussed in a recent review much of
the efforts over the past decade have been focused on
achieving selectivity for a specific G-quadruplex.35 Despite
this, there is evidence that the most clinically efficacious
G-quadruplex ligands are those that target multiple types of
G-quadruplexes, such as in the case of triarylpyridine 20A.36
Whilst there are a number of G-quadruplex ligands
currently in clinical trials, there are, as yet no ligands
approved for clinical use. The formation of more
G-quadruplex structures during the S phase of the cell cycle
in neoplasia continues to endorse the need for a greater
range of potential ligands, both to probe selectivity and as
lead compounds for therapeutic agents as more is
understood about how these structures are modulated in
human cells at different points within the cycle, having a
diverse range of potential ligands may help to make
personalised cancer chemotherapy a reality.
General preparation example – 2c
Tryptamine (390 mg, 0.00245 mol) and 9,10-
dibromocarbaldehyde (250 mg) were stirred in dry DCM (40
ml) over molecular sieves. The reaction mixture was refluxed
for 12 h under N2 environment. The resultant mixture was
monitored via TLC which showed the consumption of both
starting materials. After TLC analysis, the crude mixture was
left to cool down to room temperature. The resulting yellow
solid 2c was filtered and it was dried under vacuum before
Fig. 4 Surface energy model of ligand 2a intercalating parallel (PDB
entry139d) and antiparallel (PDB entry 6IMS) G-quadruplex strands
(UCSF Chimera 1.15).
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being recrystallised from methanol to give (0.44 g, 80%) yield.
1H NMR (400 MHz; d6-DMSO) δ = 3.68 (4H, t, J = 6.65 Hz,
CH-8) 4.26 (4H, t, J = 8.66 Hz, CH2-7), 7.01 (2H, t, J = 8.76 Hz,
CH-6), 7.10 (2H, t, J = 8.78 Hz, CH-5) 7.23 (2H, s, CH-4), 7.39
(2H, dddd, J = 8.0, 1.2, 0.5, 0.5 Hz, H-10), 7.424 (4H, dd, J =
6.63, 2.21 Hz, CH-3), 7.695 (2H, d, J = 7.74 Hz, CH-9), 8.123
(4H, dd, J = 6.97,2.68, CH-2)13C-NMR (600 MHz; d6-DMSO) δ
= 22.5, 46.9, 111.6, 112, 118.7, 120.2, 121.7, 122.2, 126.7,
127.5, 127.6, 130.7, 130.8, 136.4, 159.9 IR (ATR): v = 2843.46,
2922.6, 1652.99, 1621.80, 741.77 755.12 HR MS (ES) m/z =
found 519.2541, requires 520.6642 [M + 2H]+.
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